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Figure 1 A–F: Magnetic resonance T2* images showing the degree of iron overload in the patient over a six-year period 
(2008–2014). The interventricular septum (arrow) is the region of interest when assessing cardiac siderosis. A & B: 
Images taken in 2008 showing the severe cardiac siderosis (T2*: 4.5 ms) and marked hepatic iron overload (T2*: 1.3 ms; 
liver iron concentration [LIC]: 25.6 mg per g of dry weight [mg/gdw]). C & D: Images taken in 2010 showing minimal 
improvement in the cardiac iron content (T2*: 5.6 ms) despite the early effect of iron chelation on the liver (T2*: 5 ms; 
LIC: 5.3 mg/gdw). E & F: Images taken in 2014 showing appreciable lightening of both organs with improvement in 
cardiac iron content (T2*: 11.4 ms) and normalisation of hepatic iron (T2*: 14.1ms; LIC: 2 mg/gdw).
LV = left ventricle; RV = right ventricle; L = liver.
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Patients with beta thalassaemia major (TM) require regular blood transfusions in order to survive; however, these transfusions 
are associated with a risk of iron overload. Toxic 
levels of iron accumulate mainly in the liver, heart and 
endocrine organs, causing multiple complications, 
and can only be removed by the regular use of iron 
chelating agents. Different modalities exist for 
monitoring body iron levels. Serum ferritin (SF) has 
been commonly used as it is widely available and has 
a low cost. However, SF is an acute-phase reactant 
and can be spuriously elevated in the presence of 
inflammation or infection. In addition, although serial 
measurements of SF are useful in monitoring patients 
with iron overload, they do not reflect organ-specific 
iron levels. 
Historically, a liver biopsy for the assessment of 
hepatic iron (in mg per g of dry weight [mg/gdw]) has 
been the gold standard.1 A liver iron concentration 
(LIC) of >15 mg/gdw indicates severe iron overload 
and is associated with increased morbidity and 
mortality.2 However, it is invasive and does not 
accurately reflect hepatic iron content in the presence 
of heterogeneous iron distribution. The current state-
of-the-art methods for measuring organ iron overload 
are magnetic resonance imaging (MRI) techniques. 
Although R2 MRI is a robust technique for measuring 
hepatic iron content, MRI T2* is more widely available 
and can assess both hepatic and cardiac iron.3,4 The 
latter is particularly important as in many cases 
neither SF nor LIC correlates well with cardiac iron 
content.4 For instance, a patient can have a relatively 
low SF level and LIC but still have dangerously high 
levels of myocardial iron. Anderson et al. showed that 
a cardiac MRI T2* of <20 ms is indicative of cardiac 
iron overload, while measurements of <10 ms are 
associated with severe cardiac siderosis.4 Recent 
data confirm that patients with cardiac MRI T2* of 
<10 ms are at a much higher risk of heart failure and 
other cardiac events than those with measurements 
of >10 ms.5 Using MRI techniques, it is possible to 
evaluate iron overload in different organs in a non-
invasive manner as well as safely monitor the effects of 
chelation therapy. 
MRI T2* imaging has been used at the Sultan 
Qaboos University Hospital (SQUH) in Muscat, Oman, 
as part of the regular management of TM patients 
since 2006. MRIs are performed using the 1.5T 
Siemens Sonata scanner (Siemens Healthcare Corp., 
Malvern, Pennsylvania, USA) according to protocols 
described by Anderson et al. and Westwood et al.4,6 T2* 
values were calculated using software from CMRtools 
(Cardiovascular Imaging Solutions Ltd., London, UK). 
Hepatic iron (LIC) was calculated from liver MRI T2* 
scans as described by Wood et al.7 
Comment
Figures 1 and 2 show MRI T2* images of a patient with 
TM over a six-year period. The patient was referred 
to SQUH in 1991 at the age of seven years and had 
never previously been chelated. He subsequently 
underwent different chelation protocols including 
monotherapy with deferoxamine (DFO) from 1991–
2001 and combined DFO and deferiprone (DFP) from 
2001–2005. Poor family compliance with the chelation 
therapy resulted in the patient having persistently 
high SF levels, ranging between 6,000 and 7,500 ng/
mL (normal range: 20–300 ng/mL). In 2005, he 
was enrolled in a multicentre trial on the efficacy of 
deferasirox. Although his SF levels had fallen from 
7,400 ng/mL to 6,042 ng/mL by the end of the trial 
in 2008, MRI T2* images revealed significant cardiac 
and hepatic siderosis (4.5 ms and 25.6 mg/gdw, 
respectively) [Figures 1A & B]. Intensive chelation 
with continuous intravenous DFO and oral DFP was 
recommended; however, the patient was reluctant to 
commit to the prolonged hospitalisation necessary for 
this protocol. After further counselling, the patient 
opted to use continuous subcutaneous DFO (4 gm/
day) and DFP (100 mg/kg/day) and subsequently 
demonstrated excellent compliance to this treatment. 
Reviewing the MRI T2* images during follow-up 
helped to support this compliance, as the patient was 
able to see for himself that the images progressively 
became lighter in colour with the decrease in iron 
overload over time [Figures 1A–F]. 
Figure 1 highlights the advantage of MRI T2* in 
assessing and monitoring organ-specific iron levels. A 
review of the patient’s serial MRI T2* results revealed 
that his hepatic iron content decreased well before any 
change in the cardiac iron levels. This is consistent 
with the findings demonstrated by Noetzli et al. in a 
longitudinal study; there appears to be a ‘lag’ period 
for iron overload and the effect of chelation therapy 
on the liver and heart, whereby the former is the first 
organ to ‘load’ with iron if chelation is inadequate.8 
The liver is also the organ that shows an earlier effect 
of chelation compared to the heart [Figures 1C & D].8 
Recent imaging studies [Figures 1E & F] of this patient 
showed that the cardiac MRI T2* had improved to 11.4 
ms and his hepatic iron content had fallen to normal 
levels (2 mg/gdw). His latest SF level was 403 ng/mL. 
It is probable that removal of cardiac iron could have 
been achieved much faster if intravenous DFO had 
been used.
This case highlights a number of points. Firstly, 
it underlines that the use of MRI T2* can be an 
invaluable tool in the assessment and follow-up of 
organ iron load. Secondly, severe iron overload may 
take a long time to respond to chelation therapy. It is 
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important that neither the physician nor the patient 
expect rapid results, particularly regarding cardiac 
iron. Persistent counselling and support are essential. 
Thirdly, as illustrated in this case and as confirmed 
in other studies, SF is a poor indicator of cardiac 
siderosis. Finally, this case demonstrates that it is rarely 
too late to reverse severe iron overload. Continuous 
efforts should therefore be made in counselling non-
compliant patients.
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Figure 2A & B: Analysis of the liver T2* magnetic resonance image (MRI) using CMRtools (Cardiovascular Imaging 
Solutions Ltd., London, UK). The greater the tissue iron load, the lower the T2* value. A: Liver MRI analysis in 2008, with 
a T2* of 1.3 ms (25.6 mg per g of dry weight [mg/gdw]). B: By 2014, a marked improvement can be observed (T2*: 14.1 
ms; iron content: 2 mg/gdw).
